Hospital Universitari Dexeus Grupo Quironsalud
- Address
- lock Available on a paid plan
Medical Oncology at Hospital Universitari Dexeus Grupo Quironsalud
Clinical research here is strongly focused on neoplasms, with a broad mix of studies in breast cancer, non-small cell lung cancer, melanoma, and other advanced solid tumors. Many trials aim to test new treatment options, compare them with current standards, and improve outcomes for people with difficult-to-treat cancers.
- Studies in breast cancer include hormone receptor-positive, HER2-negative disease, HER2-positive disease, and triple-negative breast cancer, often evaluating whether newer therapies can improve survival and disease control.
- A major research focus is non-small cell lung cancer, including EGFR-, KRAS-, RET-, MET-, and HER2-driven subtypes, with trials designed to refine targeted treatment and immunotherapy strategies.
- There is also active work in melanoma, classical Hodgkin lymphoma, and broader solid tumors, exploring more effective ways to treat advanced or resectable disease.
Across the site’s portfolio, investigators are also studying supportive and specialized care in areas such as female reproductive health, pregnancy complications, and infertility, showing a wider interest in improving both cancer care and related patient outcomes.
Research in lung cancer and thoracic oncology
This site has a particularly large number of trials in advanced non-small cell lung cancer and related thoracic cancers. The research is centered on testing targeted therapies, immunotherapy combinations, and perioperative approaches to improve response rates, survival, and long-term disease control.
- Trials in EGFR-mutated, KRAS G12C-mutated, RET fusion-positive, HER2-altered, and MET-driven lung cancer are evaluating precision medicine approaches for specific tumor profiles.
- Several studies focus on resectable or early-stage lung cancer, aiming to strengthen treatment before or after surgery and reduce the risk of recurrence.
- Other projects examine small cell lung cancer and metastatic disease, with the goal of improving outcomes when standard options are limited.
At Hospital Universitari Dexeus Grupo Quironsalud, this area reflects a major effort to match each patient’s tumor biology with more precise and effective treatment strategies.
Breast cancer and hormone-driven tumors
Another major research stream involves breast neoplasms, especially advanced and early-stage disease with hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative subtypes. The trials are designed to improve treatment effectiveness, reduce recurrence, and explore better options after standard therapies.
- Studies in HER2-positive breast cancer are assessing new treatment sequences and combinations to strengthen response in both early and metastatic disease.
- Research in HR-positive/HER2-negative breast cancer is focused on overcoming resistance and improving progression-free survival in advanced cases.
- Trials in triple-negative breast cancer aim to expand options for one of the most challenging breast cancer subtypes.
These studies also include work on symptom management and quality of life, such as reducing vasomotor symptoms linked to endocrine therapy.
Melanoma, hematologic cancers, and other advanced malignancies
The research portfolio also includes studies in melanoma, advanced classical Hodgkin lymphoma, and a range of advanced solid tumors. These trials are typically aimed at improving immune-based treatment approaches, expanding options for patients with recurrent disease, and identifying more effective combinations than current standards.
- In melanoma, the focus is on perioperative and adjuvant strategies that may lower the chance of relapse after surgery.
- In Hodgkin lymphoma, research is evaluating new frontline treatment approaches to improve disease control.
- Broader solid tumor studies are exploring new therapies for patients whose cancers have progressed or no longer respond to available treatments.
These efforts show the site’s interest in both disease-specific innovation and more general cancer treatment development.
Women’s health, pregnancy, and reproductive medicine
Beyond oncology, the site is also involved in clinical trials related to female urogenital diseases, pregnancy complications, and infertility. These studies address common but important conditions that affect reproductive health, comfort, and pregnancy outcomes.
- Research in infertility is examining ways to support assisted reproductive care and improve embryo-related outcomes.
- Trials in preeclampsia are focused on prevention and maternal-fetal safety during pregnancy.
- Studies in genitourinary syndrome of menopause are evaluating better symptom relief and quality of life for women after menopause.
These projects broaden the clinical research profile of Hospital Universitari Dexeus Grupo Quironsalud beyond cancer care, while still emphasizing practical improvements for patients.
Supportive care and specialized therapies
Some studies at this site focus on supportive and highly specialized medical care, including conditions linked to hormonal disease, immune system disorders, and respiratory tract disease. The purpose of these trials is often to improve symptom control, safety, and everyday functioning alongside disease treatment.
- Studies in menopause-related symptoms and heartburn or reflux aim to improve comfort and tolerability in everyday care.
- Research in achondroplasia and bronchopulmonary dysplasia reflects interest in rare or specialized conditions affecting growth and early-life health.
- Other work explores cellular therapies and regenerative approaches for selected patient groups.
This mix of research highlights a site that combines advanced oncology trials with broader clinical questions relevant to women’s health, pediatrics, and supportive treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 219 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 215 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 42 by active trials.
lock +41 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +25 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitari Dexeus Grupo Quironsalud
lock Showing 1 of 146 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors | Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. | Phase II | Not Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 219 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 27 | Unknown | 2019-02-13 | 2026-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
